TRIAMTERENE Drug Patent Profile

When do Triamterene patents expire, and what generic alternatives are available?

Triamterene is a drug marketed by Agnitio, Biocon Generics, Ani Pharms, Cadila, Chartwell Rx, Duramed Pharms Barr, Lannett Co Inc, Macleods Pharms Ltd, Novartis, Pharmobedient, Sandoz, Vitarine, Am Therap, Apotex Inc, Pliva, Quantum Pharmics, Rubicon Research, Watson Labs, and Zydus Pharms. and is included in twenty-five NDAs.

The generic ingredient in TRIAMTERENE is hydrochlorothiazide; triamterene. There are thirty-two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; triamterene profile page.

Summary for TRIAMTERENE

US Patents:	0
Applicants:	19
NDAs:	25

US Patents and Regulatory Information for TRIAMTERENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	TRIAMTERENE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; triamterene	TABLET;ORAL	071969-001	Apr 17, 1988		DISCN	No	No
Zydus Pharms	TRIAMTERENE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; triamterene	TABLET;ORAL	208360-001	Jun 29, 2018	AB	RX	No	No
Agnitio	TRIAMTERENE	triamterene	CAPSULE;ORAL	211581-001	Aug 19, 2019	AB	RX	No	No

Triamterene: Investment and Fundamentals Analysis

Last updated: February 19, 2026

Triamterene, a potassium-sparing diuretic, presents a mature but stable asset within the pharmaceutical market. Its established efficacy in managing hypertension and edema, coupled with a consistent demand profile, positions it as a predictable revenue generator. However, market saturation, generic competition, and limited pipeline expansion opportunities characterize its investment landscape.

What is Triamterene?

Triamterene is a pteridine derivative that acts as a direct inhibitor of epithelial sodium channels (ENaC) in the distal tubules of the kidney. This mechanism prevents sodium reabsorption, leading to increased excretion of sodium and water, thereby reducing blood volume and blood pressure. Unlike thiazide diuretics, triamterene does not significantly affect potassium excretion, making it a valuable option for patients at risk of hypokalemia. It is commonly formulated in combination with hydrochlorothiazide, a thiazide diuretic, to enhance efficacy and provide synergistic effects in blood pressure management.

The primary indications for triamterene are:

• Hypertension: Used alone or in combination with other antihypertensive agents to lower elevated blood pressure.
• Edema: Treatment of edema associated with congestive heart failure, liver cirrhosis, and renal disease.

Triamterene was first approved by the U.S. Food and Drug Administration (FDA) in 1964. Its long history of clinical use has established a robust safety and efficacy profile.

Patent Landscape and Exclusivity

The original patents for triamterene have long expired, placing the active pharmaceutical ingredient (API) in the public domain. This has led to widespread generic availability, significantly impacting market dynamics and pricing.

• Original Compound Patents: Expired decades ago.
• Formulation Patents: While some specific formulations or combination products may have held patent protection, these have also largely expired or are nearing expiry. For example, the combination product Dyazide (triamterene/hydrochlorothiazide) saw its patent exclusivity lapse, paving the way for generic versions.
• Manufacturing Process Patents: These may exist for specific, novel manufacturing processes but do not grant market exclusivity for the drug itself.
• New Use Patents: There is limited evidence of significant new use patents being granted or actively pursued for triamterene in recent years.

The absence of significant patent-protected exclusivity means that any company seeking to invest in triamterene must focus on manufacturing efficiency, supply chain management, and market penetration strategies for generic products.

Market Dynamics and Competition

The market for triamterene is characterized by intense competition among generic manufacturers. This competition exerts downward pressure on prices and profit margins.

• Generic Penetration: Triamterene, both as a monotherapy and in combination products, has a high generic penetration rate in major markets like the United States and Europe.
• Key Competitors: The market includes numerous generic drug manufacturers. Major players in the generic diuretic space often produce triamterene. These include companies like Teva Pharmaceuticals, Mylan (now Viatris), Aurobindo Pharma, and Sun Pharmaceutical Industries.
• Pricing: The average selling price (ASP) for generic triamterene is low, driven by volume and competition. Price fluctuations are primarily influenced by supply-demand dynamics and competitive bidding in institutional markets.
• Market Size: The global market for diuretics is substantial, with triamterene holding a segment within it. Precise market size data for triamterene alone is difficult to isolate due to its common use in combination products and the fragmented nature of the generic market. However, the broader antihypertensive and edema treatment markets are worth billions of dollars annually.

Manufacturing and Supply Chain

Manufacturing triamterene involves complex chemical synthesis. Key considerations for manufacturers include:

• API Sourcing: Secure and cost-effective sourcing of the triamterene API is critical. Many API manufacturers are located in India and China, which offer cost advantages.
• Good Manufacturing Practices (GMP): Strict adherence to GMP regulations is mandatory to ensure product quality, safety, and regulatory compliance.
• Economies of Scale: To remain competitive, manufacturers must achieve significant economies of scale. High-volume production reduces per-unit manufacturing costs.
• Supply Chain Reliability: A robust and reliable supply chain is essential to meet consistent market demand and avoid stock-outs, which can lead to loss of market share.
• Formulation Expertise: Companies specializing in solid oral dosage forms are well-positioned to manufacture triamterene tablets.

Table 1 outlines typical manufacturing considerations:

Consideration	Description	Impact on Investment
API Cost	Cost of raw materials for triamterene synthesis.	Directly impacts gross margins.
Manufacturing Scale	Production volume and plant capacity.	Determines cost per unit and ability to meet demand.
Regulatory Compliance	Adherence to FDA, EMA, and other health authority standards.	Essential for market access; non-compliance halts sales.
Quality Control	Rigorous testing to ensure purity, potency, and stability.	Protects brand reputation and patient safety.
Distribution Network	Efficient logistics to reach wholesalers, pharmacies, and healthcare providers.	Key to market penetration and timely product availability.

Regulatory Landscape

As a long-approved drug, triamterene is subject to established regulatory frameworks.

• ANDA Pathway: Generic manufacturers seeking to market triamterene in the U.S. must file an Abbreviated New Drug Application (ANDA) with the FDA. This demonstrates bioequivalence to the reference listed drug.
• Post-Approval Surveillance: Manufacturers are required to monitor product safety and report adverse events through pharmacovigilance programs.
• Facility Inspections: Manufacturing facilities are subject to periodic inspections by regulatory authorities to ensure ongoing compliance.
• Labeling Requirements: Prescribing information and patient labeling must be accurate and updated as needed based on new safety information.

Financial Performance and Investment Thesis

The investment thesis for triamterene revolves around its stable, albeit low-growth, revenue streams. Companies that excel in efficient manufacturing and distribution are best positioned.

Key Financial Metrics to Consider:

• Revenue: Steady revenue from a high-volume, low-margin product. Growth is primarily driven by market share gains rather than price increases.
• Gross Margins: Generally low for generic products due to intense competition. Efficiency in API sourcing and manufacturing is paramount to maintaining profitability.
• Operating Expenses: Marketing and sales expenses are typically lower for established generics compared to innovative drugs. R&D expenditure is minimal, focusing on process improvement rather than drug discovery.
• Market Share: Sustaining or growing market share is a primary objective. This is achieved through competitive pricing, reliable supply, and strong relationships with distributors.

Investment Scenario Analysis:

An investment in a company that manufactures triamterene is fundamentally a bet on operational excellence in the generic pharmaceutical space.

• Strengths:

  • Predictable Demand: Hypertension and edema are chronic conditions requiring long-term treatment.
  • Established Safety and Efficacy: Decades of clinical use reduce product development risk.
  • Low R&D Burden: No significant investment required for new drug discovery or extensive clinical trials.
  • Barriers to Entry (for efficient manufacturing): While patents are expired, establishing cost-effective, high-volume, GMP-compliant manufacturing can be a barrier.

• Weaknesses:

  • Price Erosion: Intense generic competition drives down prices.
  • Limited Growth Potential: The drug’s therapeutic applications are well-established, with little scope for significant new indications.
  • Commoditization: Triamterene is largely a commoditized product.
  • Reliance on Supply Chain: Vulnerability to API price fluctuations and supply chain disruptions.

• Opportunities:

  • Emerging Markets: Growth in healthcare infrastructure and access to medicines in developing economies.
  • Portfolio Diversification: Including triamterene in a broader generic portfolio can create synergies in sales and distribution.
  • Combination Product Development (limited): While original combination patents are expired, innovative delivery methods or novel combinations might offer marginal differentiation, though this is highly challenging.

• Threats:

  • Increased Competition: New generic entrants can further pressure prices.
  • Regulatory Changes: Unexpected changes in FDA or EMA regulations could increase compliance costs.
  • Therapeutic Advancements: Development of novel treatments for hypertension or edema could reduce demand for older drug classes.
  • Shortages and Recalls: Product quality issues leading to recalls can severely damage reputation and market position.

Future Outlook

The future outlook for triamterene remains stable, characterized by consistent demand but limited growth. Companies that can optimize their manufacturing processes, secure favorable API pricing, and maintain efficient distribution channels will continue to generate reliable returns. Innovation in this segment is unlikely to be driven by new drug discoveries but rather by incremental improvements in manufacturing efficiency and supply chain resilience. The market will continue to be dominated by generic players focused on volume and cost leadership.

Key Takeaways

Triamterene, a well-established potassium-sparing diuretic, operates within a mature generic market characterized by intense competition and price sensitivity. Its investment appeal lies in its predictable demand for hypertension and edema management, driven by chronic disease prevalence. However, the absence of patent exclusivity means profitability hinges on manufacturing efficiency, cost-effective API sourcing, and robust supply chain management. Companies can sustain revenue streams by focusing on operational excellence and market share within the generic segment, rather than expecting significant growth or innovative pipeline contributions.

FAQs

What is the primary mechanism of action for triamterene?

Triamterene acts as a direct inhibitor of epithelial sodium channels (ENaC) in the distal tubules of the kidney, increasing the excretion of sodium and water while conserving potassium.

Has triamterene lost patent protection, and what are the implications?

Yes, the original patents for triamterene have long expired, leading to widespread generic availability and intense competition among manufacturers.

What are the main indications for triamterene?

The primary indications for triamterene are the management of hypertension and edema associated with conditions like congestive heart failure and liver cirrhosis.

What is the typical profit margin for a generic triamterene product?

Profit margins for generic triamterene are generally low due to significant price competition among manufacturers, making operational efficiency crucial for profitability.

What are the key risks associated with investing in a triamterene manufacturer?

Key risks include intense price erosion from generic competition, potential supply chain disruptions, regulatory changes, and the possibility of therapeutic advancements reducing demand for older drug classes.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations

[2] Seldin, D. W., & Giebisch, G. (1997). Diuretics. The Journal of Clinical Investigation, 100(10), 2495–2498. doi: 10.1172/JCI119474

[3] Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Greenlee, M. B., Izzo Jr, J. L., Jones, D. W., Materson, B. J., Oparil, S., Osei, K., Perry, G. J., Sacks, F. M., Smith, C. E., Svetkey, L. P., Wegener, S., & St. John, K. (2003). Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Hypertension, 42(6), 1206–1252. doi: 10.1161/01.HYP.0000103880.12059.44

[4] Generic Pharmaceutical Association. (n.d.). Generic Drug Facts. Retrieved from https://www.pbgc.org/industry-overview/ (Note: While this link points to PBGC, the actual GPhA facts are often published on their main site or through industry reports. Accessing specific, dated GPhA reports for exact market share figures is challenging, but the principle of generic market dynamics is well-established.)